

**§516.52 Availability for public disclosure of data and information in requests.**

(a) FDA will not publicly disclose the existence of a request for MUMS-drug designation under section 573 of the act prior to final FDA action on the request unless the existence of the request has been previously publicly disclosed or acknowledged.

(b) Whether or not the existence of a pending request for designation has been publicly disclosed or acknowledged, no data or information in the request are available for public disclosure prior to final FDA action on the request.

(c) Except as provided in paragraph (d) of this section, upon final FDA action on a request for designation, the public availability of data and information in the request will be determined in accordance with part 20 of this chapter and other applicable statutes and regulations.

(d) In accordance with §516.28, FDA will make a cumulative list of all MUMS-drug designations available to the public and update such list periodically. In accordance with §516.29, FDA will give public notice of the termination of all MUMS-drug designations.

**Subpart C—Index of Legally Marketed Unapproved New Animal Drugs for Minor Species**

SOURCE: 72 FR 69121, Dec. 6, 2007, unless otherwise noted.

**§516.111 Scope of this subpart.**

This subpart implements section 572 of the act and provides standards and procedures to establish an index of legally marketed unapproved new animal drugs. This subpart applies only to minor species and not to minor use in major species. This index is only available for new animal drugs intended for use in a minor species for which there is a reasonable certainty that the animal or edible products from the animal will not be consumed by humans or food-producing animals and for new animal drugs intended for use only in a hatchery, tank, pond, or other similar contained man-made structure in an early, nonfood life stage of a food-pro-

ducing minor species, where safety for humans is demonstrated in accordance with the standard of section 512(d) of the act (including, for an antimicrobial new animal drug, with respect to antimicrobial resistance). The index shall not include a new animal drug that is contained in, or a product of, a transgenic animal. Among its topics, this subpart sets forth the standards and procedures for:

- (a) Investigational exemptions for indexing purposes;
- (b) Submissions to FDA of requests for determination of eligibility of a new animal drug for indexing;
- (c) Establishment and operation of expert panels;
- (d) Submissions to FDA of requests for addition of a new animal drug to the index;
- (e) Modifications to index listings;
- (f) Publication of the index; and
- (g) Records and reports.

**§516.115 Definitions.**

(a) The following definitions of terms apply only in the context of subpart C of this part:

*Director OMUMS* means the Director of the Office of Minor Use and Minor Species Animal Drug Development of the FDA Center for Veterinary Medicine.

*Holder* means the requestor of an index listing after the request is granted and the new animal drug is added to the index.

*Index* means FDA's list of legally marketed unapproved new animal drugs for minor species.

*Intended use* has the same meaning as that given in §516.13 of this chapter.

*Qualified expert panel* means a panel that is composed of experts qualified by scientific training and experience to evaluate the target animal safety and effectiveness of a new animal drug under consideration for indexing.

*Requestor* means the person making a request for determination of eligibility for indexing or a request for addition to the index.

*Transgenic animal* means an animal whose genome contains a nucleotide sequence that has been intentionally modified in vitro, and the progeny of such an animal, provided that the term 'transgenic animal' does not include an